Skip to main content Skip to section navigation Skip to footer
Capricor Therapeutics, Inc.
  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors (DMD)
  • Our Science
    • CAP-1002 (Cell Therapy)
    • Exosomes Technology
    • Publications
    • Strategic Partnerships
  • Pipeline
    • Pipeline
    • Duchenne Muscular Dystrophy Overview
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Latest Proxy Statement and Annual Report
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
Dec 19, 2019 1:14 pm EST

Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

Dec 17, 2019 1:52 pm EST

Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

Nov 07, 2019 4:00 pm EST

Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update

Nov 01, 2019 9:00 am EDT

Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7

Oct 21, 2019 9:25 am EDT

Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Oct 07, 2019 6:30 am EDT

Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

Oct 02, 2019 9:15 am EDT

Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET

Sep 24, 2019 7:30 am EDT

Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

Sep 17, 2019 7:00 am EDT

Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

Sep 06, 2019 7:30 am EDT

Capricor Therapeutics to Present at Upcoming Conferences

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • …Page 25
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Visit us on Linkedin
  • Visit us on Facebook
  • Visit us on Instagram
  • Visit us on Twitter
©2023 Capricor Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences